CSRC Session at the DIA Annual Meeting — June 27, 2012

ONCOLOGY MEDICATIONS:  STATE-OF-THE-ART IDENTIFICATION AND MANAGEMENT OF POTENTIAL CV SAFETY ISSUES DURING DEVELOPMENT

 

 

CSRC Session Overview and Objectives:

Overview:

Increasingly cardiac safety issues have arisen as a concern in the development  of oncology medications.  This session will focus on the potential safety issues of cardiotoxicity and QT prolongation and arrhythmogenesis and discuss their identification and potential management strategies.  In addition, a state-of-the-art framework for collecting potential cardiac safety adverse events will be discussed and audience participation will be encouraged.  The attendee will gain deeper theoretical and practical insight into the cardiac safety evaluation and risk-management of oncology medications during their development

 

Objectives

  • To understand the techniques to identify myocardial toxicity during the development of oncology medications
  • To learn the different approaches to assessing the potential for a development-stage oncologic compound to be arrhythmogenic and how to manage any potential risks
  • To understand how to proactively assess potential cardiac adverse events using a standardized methodology
  • To formulate theoretical and practical insight into the cardiac safety evaluation and risk-management of oncology medications in development

 

CSRC at the DIA 2012

DIA 1

DIA 2

 www.diahome.org/DIA2012